Cover image of asfotase alfa outcome statement


Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date: 
26 October 2020
Last updated: 
3 February 2021
Publication type: 
Intended audience: 
General public

This document summarises the Chief Medical Officer's consideration of Alexion Pharmaceuticals Australasia Pty Ltd's application to include asfotase alfa (Strensiq®) on the Life Saving Drugs Program for the treatment of peri-natal and infantile onset hypophosphatasia.